BMP-Non-Responsive Sca1<sup>+</sup>CD73<sup>+</sup>CD44<sup>+</sup> Mouse Bone Marrow Derived Osteoprogenitor Cells Respond to Combination of VEGF and BMP-6 to Display Enhanced Osteoblastic Differentiation and Ectopic Bone Formation

Vedavathi Madhu, Ching-Ju Li, Abhijit S. Dighe, Gary Balian, Quanjun Cui

Orthopaedic Research Laboratories, Department of Orthopaedic Surgery, University of Virginia, Charlottesville, Virginia, United States of America

Abstract

Clinical trials on fracture repair have challenged the effectiveness of bone morphogenetic proteins (BMPs) but suggest that delivery of mesenchymal stem cells (MSCs) might be beneficial. It has also been reported that BMPs could not increase mineralization in several MSCs populations, which adds ambiguity to the use of BMPs. However, an exogenous supply of MSCs combined with vascular endothelial growth factor (VEGF) and BMPs is reported to synergistically enhance fracture repair in animal models. To elucidate the mechanism of this synergy, we investigated the osteoblastic differentiation of cloned mouse bone marrow derived MSCs (D1 cells) in vitro in response to human recombinant proteins of VEGF, BMPs (-2, -4, -6, -7) and the combination of VEGF with BMP-6 (most potent BMP). We further investigated ectopic bone formation induced by MSCs pre-conditioned with VEGF, BMP-6 or both. No significant increase in mineralization, phosphorylation of Smads 1/5/8 and expression of the ALP, COL1A1 and ostein genes was observed upon addition of VEGF or BMPs alone to the cells in culture. The lack of CD105, Alk1 and Alk6 expression in D1 cells correlated with poor response to BMPs indicating that a greater care in the selection of MSCs is necessary. Interestingly, the combination of VEGF and BMP-6 significantly increased the expression of ALP, COL1A1 and ostein genes and D1 cells pre-conditioned with VEGF and BMP-6 induced greater bone formation in vivo than the non-conditioned control cells or the cells pre-conditioned with either VEGF or BMP-6 alone. This enhanced bone formation by MSCs correlated with higher CADM1 expression and OPG/RANKL ratio in the implants. Thus, combined action of VEGF and BMP on MSCs enhances osteoblastic differentiation of MSCs and increases their bone forming ability, which cannot be achieved through use of BMPs alone. This strategy can be effectively used for bone repair.

Introduction

Injuries to the postnatal skeleton are repaired through natural healing which is a complex, well-orchestrated process that recapitulates the pathway of embryonic development. It involves a variety of cell types and signaling molecules. Deficiencies in mesenchymal stem cells (MSCs) [1–2], angiogenesis induced by vascular endothelial growth factor (VEGF) [3–4] and bone morphogenetic proteins (BMPs) signaling [5–7] are associated with fractures that do not heal. It is estimated that of the 7.9 million fractures sustained each year in the United States, 5% to 20% result in delayed or impaired healing [8].

Clinical trials conducted using BMP-2 and BMP-7 to enhance bone repair showed that the method is not cost effective [9–11]. A recent review of 11 randomized controlled trials and 4 economical evaluations of BMPs for fracture repair concluded that only one study showed a difference in fracture healing between the BMP treated and control groups, but there was some suggestion that no second intervention was needed in the groups treated with BMP [10]. Several investigators have reported that BMPs fail to enhance mineralization and ALP expression in MSCs in vitro [12–21]; however the reasons that underlie the non-responsiveness of these cells are not understood. The limited success of clinical trials that used BMP-2 or BMP-7 could be due to suboptimal response of the osteoprogenitor cells as these stem cells play a pivotal role in BMP-induced bone repair [22]. The clinical trials using MSCs have shown promising results for fracture repair [23–24] which can be further enhanced through combined use of MSCs and BMPs if BMP-responsiveness of MSCs is better understood.

Combined delivery of MSCs, VEGF and BMPs (BMP-2, -4 and -7) has been immensely successful in enhancing fracture repair and bone formation in various animal models. We have systematically reviewed these studies recently [25]. These studies have shown that delivery of any single factor or combination of any two factors was less effective in inducing osteogenesis in comparison to that...
induced by MSCs, VEGF and BMP together. Synergistic enhancement of bone formation was BMP-type specific as VEGF and MSCs showed more influence on osteogenesis with BMP-4 than that with BMP-2 whereas there was no synergy with BMP-7 [26–29].

Since BMP-6 is reported to be more potent than BMP-2, -4 and -7 [29–30] and BMP-6 is resistant to inhibition by noggin while other BMPs are susceptible to noggin [27] which is predominantly expressed in non-union fractures [6–7], BMP-6 would be an ideal candidate to enhance fracture repair with VEGF and MSCs. We have demonstrated earlier that cloned mouse bone marrow derived mesenchymal stem cells (mBMSCs) (D1 cells) co-expressing human VEGF and BMP-6 genes or VEGF and lim-7 [29–30] and BMP-6 is resistant to inhibition by noggin while other BMPs are susceptible to noggin [31] which is predominantly expressed in non-union fractures [6–7] and BMP-6 was designated as basal medium (BM) and to induce osteogenesis, 10 mM β-glycerophosphate was added to BM to prepare osteogenic medium (OM). For all the experiments related to osteogenesis, the D1 cells were seeded at a density of 0.5×10^5 cells/cm² in a 24-well plate. Human recombinant proteins BMP-2, -4, -6; VEGF (Prospect, Israel) and BMP-9 (Assay Designs/Enzo Life Sciences, USA) were added to OM at the specified concentrations. Culture medium was replaced twice a week. The mineralization was determined using OM supplemented with 1, 10 and 100 ng of VEGF or individual BMPs and OM supplemented with a combination of 10 ng of VEGF and 10 ng of BMP-6. To determine mRNA expression of runx2 and osteocalcin in presence of BMPs, the cells were grown in BM, OM and OM supplemented with 10 ng of BMP proteins. The Smads 1/5/8 phosphorylation was quantified using cells grown in BM, OM, OM containing 10 ng VEGF or 10 ng individual BMPs or combination of 10 ng VEGF and 10 ng BMP-6. The influence of cross-talk between VEGF and BMP-6 pathways on expression of osteogenic genes was investigated in cells grown in BM, OM and OM supplemented with 10 ng VEGF or BMP-6 or both. To investigate if pre-conditioning of the cells improves their bone formation ability, cells were grown in OM, OM supplemented with 10 ng VEGF or BMP-6 or both for 7 days and then implanted in sub-cutaneous tissues of Balb/c mice.

The staining of cytoplasm and the nuclei

The D1 cells were seeded at a density of 1×10^5 cells/cm² in a 24-well plate and maintained in BM for 4 days. At day 5, the cells were stained using the methods described earlier [35].

Alicizan red and Sudan IV staining

Mineralization was quantified using alizarin red staining as described earlier [35]. To determine if the D1 cells are capable of differentiation along an adipogenic lineage, the cells were cultured in OM containing 10⁻² M dexamethasone for 14 days to induce adipogenesis. The differentiated cells were stained with Sudan IV, a stain for fat, counterstained with hematoxylin, and visualized by light microscopy (20X).

RNA extraction, preparation of cDNA, conventional PCR and real time PCR

The methods used for RNA extraction, cDNA and quantification of expression of osteogenic markers using real time PCR were described earlier [35] and the primer sequences used are described in Table 2 RNA extraction from the harvested implant was performed using a TissueLyser as described earlier [37].

A measure of the mRNA for BMP-receptors (ActR-I/Alk2, BMPR-IA/Alk3, BMPR-IB/Alk6), TGF-receptors (Alk1, TBR-1/Alk5), VEGF receptors (membrane VEGFR1/mFlt-1, soluble VEGFR1/sFlt-1, VEGFR2/Flik1) was determined using a cDNA template and gene specific primers by conventional PCR. The amplified DNA products from the PCR reactions were resolved in a 1% agarose gel and stained with ethidium bromide. The primers used are described in Table 2.

Fluorescence Activated Cell Sorting

The D1 cells were grown in BM and harvested after 5 days. A homogeneous suspension of cells in PBS was prepared, washed and then incubated with anti-mouse CD16/CD32 monoclonal antibody Clone 2.4G2 (BD Biosciences, MD, USA) to block the Fc receptors. The D1 cells (1×10⁶ cells) were stained using specific
monoclonal antibodies for 30 minutes. The list of antibodies is described in Table 3. The cells were washed three times with a solution of 1% BSA in PBS and analyzed using a FACS caliber flow cytometer (BD Biosciences, MD, USA); the data was analyzed using FloJo software (TreeStar, OR, USA).

**Western blotting**

The D1 cells were grown in BM or OM or with OM supplemented with VEGF or one of the BMP proteins or a combination of VEGF and BMP-6 for 24 hours and then lysed with SDS sample buffer without bromophenol blue (125 mM Tris-HCl pH 6.8, 150 mM β-mercaptoethanol, 1% SDS and 20% 

---

**Table 1.** List of primers used in real time PCR.

| Name              | Sequence                                      |
|-------------------|-----------------------------------------------|
| 18S Forward       | 5'-CGGCGACGACCCTTCCAGAAG-3'                   |
| 18S Reverse       | 5'-GAATCGAAGCTTCCAGAAG-3'                     |
| Alkaline Phosphatase Forward | 5'-ACGAGATCCACGAGGAGG-3'                   |
| Alkaline Phosphatase Reverse  | 5'-ACGAGATCCACGAGGAGG-3'                   |
| Runx2 Forward    | 5'-TTATCAGGGGATAGGAGG-3'                      |
| Runx2 Reverse    | 5'-AGGACAGGGGAAACAC-3'                       |
| Osterix Forward  | 5'-ACCAGGGTGCCAGCAAC-3'                      |
| Osterix Reverse  | 5'-GCCAAGTCAGGGTGTAATG-3'                    |
| Dlx5 Forward     | 5'-GATCCCTATGACGGGTGGGAC-3'                  |
| Dlx5 Reverse     | 5'-GGACTCAGATGTAATAGGGTGCTC-3'               |
| COL1A1 Forward  | 5'-CGCAGAACAGGCCTCTGTC-3'                    |
| COL1A1 Reverse  | 5'-GAATTCATGCAAGCCTCTGTC-3'                  |
| OPG Forward      | 5'-GCTGAGTTTTGTTGACAGT-3'                    |
| OPG Reverse      | 5'-GCTGGAAGTGGTTGCTCTG-3'                    |
| RANKL Forward    | 5'-TGAGGATGCTCCTGTCCTG-3'                    |
| RANKL Reverse    | 5'-CCCAACATGTTCTCAGTCC-3'                    |
| CADM1 Forward   | 5'-ATTCTGGCCCTATTTTG-3'                      |
| CADM1 Reverse   | 5'-TGCTCTCTCTGTCATGATT-3'                    |

doi:10.1371/journal.pone.0103060.t001

**Table 2.** List of primers used in PCR.

| Name              | Sequence                                      |
|-------------------|-----------------------------------------------|
| Alk1 Forward      | 5'-GTATGGGCGGCTCAAGATTTC-3'                   |
| Alk1 Reverse      | 5'-GGTATGGGAATGGGTGGTG-3'                     |
| Alk2 Forward      | 5'-CTGGAAAGACAGGGAACAAAG-3'                   |
| Alk2 Reverse      | 5'-GGCGCGGTCTCTACAGTCA-3'                     |
| Alk3 Forward      | 5'-TTATCAGGGTGGTCCTG-3'                       |
| Alk3 Reverse      | 5'-CTTATCAGGGTGGTCCTG-3'                      |
| Alk5 Forward      | 5'-GGGAAAGGATCAAGCTGATG-3'                    |
| Alk5 Reverse      | 5'-TGGAAATGAAAGAGGAGCTAG-3'                   |
| Alk6 Forward      | 5'-GAAGATCAAGATGTCCAGACAG-3'                  |
| Alk6 Reverse      | 5'-GAACAGGTGTCCCTCCTC-3'                      |
| VEGFRI2 Forward  | 5'-AGAACACAAAGAGAGAAGAGGACG-3'                |
| VEGFRI2 Reverse  | 5'-GCCACAGGGCAAAACAGTAG-3'                    |
| mFlt1 Forward    | 5'-GTCCAGGTGAAATGGGAG-3'                      |
| mFlt1 Reverse    | 5'-TGACTTTGTTGTAATAC-3'                       |
| b-actin Forward  | 5'-GCTGTATTCCCTCTTCTGACAGT-3'                 |
| b-actin Reverse  | 5'-CAGGGTGGCTATGGGTGCA-3'                     |

doi:10.1371/journal.pone.0103060.t002
Table 3. List of antibodies used for fluorescence activated cell sorting.

| Name       | Clone | Label                        | Source        |
|------------|-------|------------------------------|---------------|
| Anti Sca-1 | D7    | Phycoerythrin (PE)           | eBiosciences  |
| Anti CD105 |       | Fluorescein (FITC)           | R and D System|
| Anti CD90  | 30-H12| PE                           | eBiosciences  |
| Anti CD73  | T7/11.8| Alexa Fluor 647              |               |
| Anti CD45  | A20   | FITC                         | eBiosciences  |
| Anti CD34  | RAM 34| FITC                         | eBiosciences  |
| Anti CD44  | IM7   | PE                           | eBiosciences  |
| Anti CD146 | ME-9F1| PE                           | Biolegend     |
| Anti CD133 | 13A4  | Peridinin-chlorophyll-protein complex (PerCP) | eBiosciences |
| Anti Nestin| 25    | Alexa Fluor 647              | BD Biosciences|

glycerol) in the presence of IX protease inhibitor cocktail (Santa Cruz Biotechnology) and 1 mM PMSF (Santa Cruz Biotechnology). The lysates were immediately placed on ice. The protein concentration was determined using a Bradford protein assay kit (Bio-rad) and equal amounts of total cell proteins were resolved on 8–12% SDS-polyacrylamide gels, electro-transferred to nitrocellulose membranes (Thermo Scientific), membranes were blocked with 5% non-fat dry milk in TBST (50 mM Tris, pH 7.6, 150 mM NaCl, 0.05% tween 20) for 1 hour at room temperature, washed and incubated overnight at 4°C in 5% BSA in TBST containing anti-phospho-Smad1/5/8 (1:1000) or anti-GAPDH antibodies (1:1000) (Cell Signaling, USA). The membranes were then incubated with HRP-conjugated secondary antibody (1:2000 in 5% non-fat dry milk in TBST) (Cell Singling, USA) for 1 hour at room temperature followed by chemiluminescent substrate for HRP antibody (Thermo Scientific) and enhancer solution (Thermo Scientific) mixed in a 1:1 ratio. The membranes were incubated in the dark with CL-Xposure films (Pierce) and the films were developed to visualize the bands. To measure the density of bands quantitatively, electronic images were generated by placing the X-ray films in a GS-800 calibrated densitometer (Bio-rad, CA, USA); images were quantified using ImageJ software.

Mice and osteogenesis induced by the D1 cells activated with VEGF or BMP-6 or the combination of VEGF and BMP-6

The D1 cells were grown in OM or OM supplemented with VEGF or BMP-6 or both for 1 week. After one week, D1 cells were harvested, suspended in PBS and were mixed (1:1 volume ratio) with Matrigel (BD Biosciences, NJ, USA) at 4°C and kept chilled in a syringe until injected into the mice. The mice were anesthetized using intra-peritoneal injection of ketamine (80 mg/ kg) and xylazine (10 mg/kg). D1 cells (passage 4, 1×10^6 cells/ 0.3 mL in Matrigel suspension) were injected on the dorsum of experimental mice. The detailed procedure is described earlier [37]. The mice from each group were sacrificed at week 2 and week 4 and at each time point harvested implants (n = 8) were used for radiography and H and E staining.

Radiographs
The details of the methods are described earlier [37]. At 2 and 4 weeks the implants were surgically removed from the subcutaneous tissue and placed on an x-ray film, radiographs were taken; the films were subsequently developed and placed into a GS-800 Calibrated Densitometer (Bio-rad, CA, USA) to convert the radiograph films into digital images. Density measurements of radiographs were performed with the ImageJ software.

Histology & Microscopy
For histological analysis, implants retrieved at week 2 and week 4 were decalcified using 0.25 M EDTA and fixed in 10% neutral buffered formalin, then dehydrated and embedded in paraffin. Six micrometer sections were stained with hematoxylin and eosin and evaluated by light microscopy.

Statistical analysis
All in vitro experiments were repeated three times and bone formation in the sub-cutaneous tissue was repeated two times. Data from one individual set are represented in the manuscript. Statistical analysis of the averages of optical densities measured at 405 nm for the Alizarin Red staining assay, average of densities from radiographs, band densities in the western blot analysis, and the relative gene expression from real time PCR was performed. To determine whether the differences between the means of different groups were statistically significant, one-way ANOVA was used, followed by the LSD test using SPSS 18.0 software. The OM group was treated as the control. Statistical significance level was set at p<0.05.

Results

In vitro mineralization of mesenchymal stem cells
Human recombinant proteins of VEGF or BMP-6 did not enhance mineralization of D1 cells at concentrations of 1 or 10 or 100 ng at day 7, 14 and 21 (Fig. 1). We therefore tested if other BMPS, BMP-2, -4 or -9 could enhance the mineralization. A similar trend was observed for all BMPs (Fig. 1). A combination of 10 ng VEGF and 10 ng BMP-6 also failed to enhance mineralization at day 7, 14 and 21.

Expression of runx2 and osterix genes and activation of Smads 1/5/8
Since VEGF, BMP-6 and other BMPs did not enhance mineralization, we determined if addition of these proteins would influence osteogenesis through modulation of the osteogenic transcription factors runx2 and osterix because both transcription factors are master regulators of osteogenesis. Surprisingly, transcription factor gene expression remained unchanged in
response to the VEGF or BMP-6 or other BMPs (Fig. 2). Furthermore, Smads 1/5/8, which are downstream modulators of the BMP-signaling pathway, did not show increased phosphorylation upon treatment of D1 cells with VEGF or BMP-6 alone. Smad 1/5/8 phosphorylation increased when the cells were treated with the combination of VEGF and BMP-6 in comparison with all other groups. However, this increase was not statistically significant.

Expression of mesenchymal stem cell surface markers and VEGF and BMP receptor genes

To determine if lack of BMP-responsiveness of D1 cells correlates with expression of receptors, we determined expression of the receptor genes and found D1 cells expression of Alk2, Alk3 but a lack of expression of Alk1 and Alk6 (Fig. 3). It is known that BMP-2 and -4 bind to Alk3 as well as to Alk6; BMP-6 binds strongly to Alk2 and weakly to Alk6, and BMP-9 binds to Alk1 and Alk2. Therefore the D1 cells showed expression of at least one receptor for each of the BMPs that we tested i.e. BMP-2, -4, -6 and -9. In addition, D1 cells expressed the TGF-β binding receptor Alk5 (Fig. 3). The main receptor for VEGF165 is VEGFR2 (Flk-1) which was expressed in D1 cells but the cells did not express either the membrane form or the soluble form of VEGFR1 (Flt-1) (Fig. 3) that binds to VEGF thereby modulating the amount of VEGF available for VEGFR2. BMP-6 enhanced gene expression for VEGFR2. BMP-6 enhanced gene expression for VEGFR2 significantly. Cell surface analysis of the D1 cells showed a surface expression profile of CD105^CD90^CD73^CD45^-CD34- (Fig. 3) which is not a classical CD105^CD90^CD73^CD45^-CD34^- mesenchymal stem cell characteristic. However, the D1 cells expressed Sca-1 (~80%), CD44 (~80%) and nestin (~30%) receptors that are known to be expressed by mesenchymal stem cells.

D1 cells are capable of differentiation into adipogenic and osteogenic lineages in vitro

The D1 cells have large nuclei that occupy most of the cytoplasmic space (Fig. 4). In the presence of dexamethasone, D1 cells in culture differentiate into an adipogenic lineage and exhibit lipid vesicles. Similarly, in the presence of osteogenic medium, the D1 cells differentiate into the osteogenic lineage in vitro and display mineralization.

Cross-talk between intracellular VEGF and BMP-6 pathways enhances expression of the ALP, COL1A1 and osterix genes

Despite our observation that VEGF, BMP-6 and combination of VEGF plus BMP-6 did not enhance mineralization of D1 cells significantly, we considered that the combination of VEGF and BMP-6 might enhance expression of osteogenic markers ALP and COL1A1 genes. When the combination of 10 ng VEGF and 10 ng BMP-6 was added to the OM, ALP and COL1A1 gene expression at day 7 was increased significantly (Fig. 5) with a corresponding significant increase in osterix gene expression.

Preconditioning of the D1 cells with the combination of VEGF and BMP-6 enhances osteogenesis in vivo

Since the combination of 10 ng VEGF and 10 ng BMP-6 enhanced expressions of ALP, COL1A1 and osterix genes at week 1, we wanted to test if preconditioning of the D1 cells with the combination of VEGF and BMP-6 for 1 week could promote osteogenesis in vivo. The preconditioning with VEGF or BMP-6 or both did not enhance osteogenesis in comparison with OM group at week 2 (Fig. 6). At week 4, however, the D1 cells preconditioned with VEGF and BMP-6 induced significantly greater osteogenesis in comparison with that induced by other
Figure 2. BMPs do not enhance Smad 1/5/8 phosphorylation and expression of runx2 and osterix genes. mRNA levels of runx2 (A) and osterix (B) were quantified using real time PCR. Smad phosphorylation was determined by western blots (C) and band intensity was quantified using ImageJ software (D).

doi:10.1371/journal.pone.0103060.g002

Figure 3. The D1 cells do not express CD105, Alk1 and Alk6 receptors. Using labeled monoclonal antibodies expression of stem cell markers (A) was determined by flow cytometry. Expression of VEGF and BMP receptors was determined by PCR followed by agarose gel electrophoresis (B).

doi:10.1371/journal.pone.0103060.g003
groups. The enhanced osteogenesis at week 4 correlated with higher ratio of mRNA levels of osteoprotegrin (OPG) to receptor activator of nuclear factor-kappaB ligand (RANKL) genes (Fig. 6) and higher expression of CADM1 (Fig. 7) in implants of D1 cells pre-conditioned with the combination of VEGF and BMP-6. We did not find any correlation between enhanced bone formation at week 4 and expression of ALP, COL1A1 genes or expression of genes of transcription factors osterix and Dlx5 in the implants at

Figure 4. The D1 cells are multipotent. The D1 cells were stained with DAPI and phalloidin to visualize cell morphology (A). Osteogenesis was assayed by staining with Alizarin Red (B) and adipogenesis was assayed by staining with Sudan IV (C).

doi:10.1371/journal.pone.0103060.g004

Figure 5. Combination of VEGF and BMP-6 enhances expression of osteogenic genes. Expression of ALP (A), COL1A1 (B), runx2 (C) and osterix (D) genes were determined by real time PCR at day 7. * denotes p<0.05.

doi:10.1371/journal.pone.0103060.g005
week 4 (Fig. 8). However, expression of ALP gene in the implants correlated with expression of osterix and Dlx5 genes while COL1A1 expression correlated with Dlx5 expression.

Discussion

The purpose of this study was to gain insight into synergistic interaction between MSCs, VEGF and BMP in enhancing fracture repair. Various growth factors (BMPs, GDF-5, TGF-β, VEGF, angiopoietins, FGF, PDGF) and cell types (platelets, endothelial cells, macrophages, MSCs, chondrocytes, osteoclasts, osteoblasts) are known to be involved during fracture repair [25]. However, involvement of MSCs, VEGF and BMP is crucial as deficiencies in these factors can lead to fractures non-unions [1–7]. Interactions between these growth factors and cells during fracture repair are complex and are not completely understood. In the last decade several investigators have shown that exogenous addition of MSCs, VEGF and BMP synergistically enhances bone formation but the exact mechanism remains elusive. It is difficult to explain this synergy through VEGF induced increased angiogenesis since our previous studies on synergistic aspect [32–33] revealed that increase in angiogenesis did not always correlate with increase in osteogenesis. While complete inhibition of angiogenesis is known to inhibit bone formation [3–4] the number of vessels and VEGF expression levels are reported to be similar in non-union fractures and fractures that heal [38–39]. Taken together, these facts suggest that synergistic enhancement of bone formation by MSCs, VEGF and BMP involves additional mechanisms than increase in angiogenesis which are not understood. Our data reveals these additional mechanisms as –1. Cross-talk between intracellular signaling pathways of VEGF and BMP-6 enhances osteoblastic differentiation of MSCs (Fig. 5) and 2. Paracrine factors produced by MSCs preconditioned with the combination of VEGF and BMP-6 modulate osteoclastogenesis through modulation of RANKL/OPG ratio (Fig. 6) and enhance osteogenic potential of MSCs as revealed by CADM1 expression (Fig. 7). CADM1 has been recently identified as a marker of higher bone forming capacity of MSCs [40]. The findings of this study shed light on possible mechanism for our earlier findings that D1 cells transiently (<1 week) expressing VEGF and BMP-6 genes [32] or VEGF and LMP-1 genes [33] induced significantly greater bone formation at week 3 than that induced by D1 cells alone or D1 cells expressing any single gene. It appears from our present study (Fig. 6) and our previous findings [32–33] that transient VEGF and BMP-6 (or LMP-1) activation of D1 cells for about a week is sufficient to warrant superior bone formation. A recent study nicely demonstrated using conditional knock-out mice that intracellular levels of VEGF and VEGF signaling in MSCs control fate of differentiation of MSCs into osteogenic versus adipogenic lineage and this function of VEGF is quite distinct than that of secreted VEGF functions [41].

Synergistic enhancement of bone formation using MSCs, VEGF and BMP is reported to be cell-type specific as VEGF
Enhancement of Osteogenesis by MSCs, VEGF and BMP-6

**Figure 7.** Enhanced expression of CADM1 in implants of D1 cells preconditioned with VEGF and BMP-6. RNA was isolated from the harvested implants and converted into cDNA. Using this cDNA as a template, mRNA expression of CADM1 was quantitatively determined in real time PCR. * denotes p<0.05.

doi:10.1371/journal.pone.0103060.g007

**Figure 8.** Expression of ALP and COL1 genes and genes for transcription factors osterix and Dlx5 in the implants of D1 cells. mRNA expression was quantified using gene specific primers and real time PCR. cDNA prepared from RNA isolated from the harvested implants was used as the template. * denotes p<0.05 compared with OM group of the respective time point, unless indicated otherwise by the horizontal lines.

doi:10.1371/journal.pone.0103060.g008
and BMP-4 co-expressing C2C12 cells made more bone in comparison with that made by NIH3T3 cells [42]. The D1 cells did not exhibit increased mineralization in response to BMPs (Fig. 1). This data is in agreement with reported findings that BMPs do not enhance mineralization in response to BMPs [12–21]. We also found that BMP-6 alone did not enhance expression of runx2, osterix, ALP, COL1A1 genes (Fig. 5) and phosphorylation of Smads 1/5/8 (Fig. 2) in D1 cells.

We investigated why D1 cells did not respond to BMPs. Although the D1 cells expressed the main receptors for BMPs, they did not express Alk1 and Alk6 (Fig. 3). Alk6 is not required for ALP expression and mineralization in MSCs [15], but we do not know if Alk6 is required for up regulation of runx2 and osterix genes and phosphorylation of Smads 1/5/8 in MSCs in response to BMP-6. Although the D1 cells were capable of differentiation into adipogenic and osteogenic lineages in vitro (Fig. 4) they did not express CD105 and CD90 receptors (Fig. 3) making it difficult to distinguish them as MSCs. Non-responsiveness of D1 cells to BMPs can be attributed to the lack of surface expression of CD105 because CD105 is the co-receptor for BMP-signaling [43]. Interestingly, we discovered that BMP-non-responsive phenotype of D1 cells in vitro could be partially overcome with preconditioning using a combination of VEGF and BMP-6 (Fig. 5). Most importantly, ability of BMP-non-responsive D1 cells to induce bone formation in vivo was significantly enhanced if the cells were pre-conditioned with VEGF and BMP-6 through paracrine modulation of RANKL/OPG ratio (Fig. 6) and expression of CADM1 (Fig. 7). This strategy can be effectively used for enhancement of fracture repair.

Conclusion

The data presented in this report demonstrates that: 1. osteoprogenitor cells that do not express CD105, Alk1 and Alk6 receptors do not respond well to BMPs in vitro, 2. These cells respond to a combination of VEGF and BMP-6 in vitro, moreover, VEGF signaling is required for a major response of MSCs to BMPs and, 3. Preconditioning of these cells with the combination of VEGF and BMP-6 enhances their ability to induce ectopic bone formation through paracrine modulation of the RANKL/OPG ratio and expression of CADM1. Overall, the data suggests that signaling interplay between the VEGF and the BMPs that are produced during fracture repair together with the endogenous or exogenously added MSCs is critical for bone repair. Therefore, greater care should be exercised while selecting MSCs for tissue engineering purposes since MSCs that do not express essential receptors might be less responsive to BMPs. Use of either MSCs alone, or VEGF or BMPs alone might not be suitable for bone repair but the combined use of MSCs, VEGF and BMP-6 is likely to be a useful approach for the development of therapies that would enhance fracture repair.

Acknowledgments

We thank Dr. Chunxi Yang, Department of Orthopaedic Surgery, Shanghai Tenth People’s Hospital (Tenth People’s Hospital of Tongji University), Shanghai 200072, China, for his help in statistical analysis of the data. We also thank Ms. Pinar Smith, School of Medicine, University of Virginia, Charlottesville, VA 22908, USA, for her technical assistance.

Author Contributions

Conceived and designed the experiments: ASD QC. Performed the experiments: VM CL ASD. Analyzed the data: VM ASD QC. Contributed reagents/materials/analysis tools: GB. Wrote the paper: ASD GB QC.

References

1. Bajada S, Marshall MJ, Wright KT, Richardson JB, Johnson WE. (2009) Decreased osteogenesis, increased cell senescence and elevated Dickkopf-1 secretion in human fracture non union stromal cells. Bone 45: 729–735.
2. Mathieu M, Rapito S, Ingrah A, Spratt D, Strieva W, et al. (2015) Decreased pool of mesenchymal stem cells is associated with altered chemokines serum levels in atrophic nonunion fractures. Bone 53: 391–398.
3. Street J, Bao M, deGuzman L, Bunting S, Peale FV Jr, et al. (2002) Vascular endothelial growth factor stimulates bone repair by promoting angiogenesis and bone turnover. Proc Natl Acad Sci U S A 99: 9566–9661.
4. Hausman MR, Schaffer MB, Majeska RJ (2001) Prevention of fracture healing in rats by an inhibitor of angiogenesis. Bone 29: 560–564.
5. Nukiwa T, Hik DJ, Reddi AH (2006) Global gene profiling reveals a downregulation of BMP gene expression in experimental atrophic nonunions compared to standard healing fractures. J Orthop Res 24: 1463–1471.
6. Fajardo M, Liu CJ, Egel K (2009) Levels of Expression for BMP-7 and Several BMP Antagonists May Play an Integral Role in a Fracture Nonunion: A Pilot Study. Clin Orthop Relat Res 467: 3071–3078.
7. Kloen P, Lautzer D, Hamdy KC (2012) Co-expression of BMPs and BMP-inhibitors in human fractures and non-unions. Bone 51: 59–68.
8. Aspengren P, Genant HK, Johansson T, Nino AJ, See K, et al. (2010) Tenoxaside for acceleration of fracture repair in humans: a prospective, randomized, double-blind study of 102 postmenopausal women with distal radial fractures. J Bone Miner Res 25: 404–414.
9. Delmar D, Smoljanovic T, Bojanic I (2012) Could the use of bone morphogenetic proteins in fracture healing do more harm than good to our patients? Int Orthop 36: 683.
10. Nauth A, Risiniemi J, McKee MD, Schemitsch EH (2009) Bone morphogenetic proteins in open fractures: past, present, and future. Injury 40: 27–31.
11. Garrison KR, Shemilt I, Donell S, Ryder J, Murphy F, et al. (2010) Bone morphogenetic protein BMP for fracture healing in adults. Cochrane Database Syst Rev 6: 1–158.
12. Chou YF, Zuk PA, Chang TL, Benhaim P, Wu BM (2011) Adipose-derived stem cells and BMP2: Part 1. BMP2-treated adipose-derived stem cells do not improve repair of segmental femoral defects. Connect Tissue Res 52: 109–110.

13. Zuk P, Chou YF, Musano F, Benhaim P, Wu BM (2011) Adipose-derived stem cells and BMP2: Part 2. BMP2 may not influence the osteogenic fate of human adipose-derived stem cells. Connect Tissue Res 52: 119–132.
14. Miano D, Agra H, Furse H, Kinura A, Naito Y, et al. (2010) Limited but heterogeneous osteogenic response of human bone marrow mesenchymal stem cells to bone morphogenetic protein-2 and serum. Growth Factors 28: 34–43.
15. Osyczka AM, Diefenderfer DL, Bhargave G, Lebov PS (2004) Different effects of BMP-2 on marrow stromal cells from human and rat bone. Cells Tissues Organs 176: 109–119.
16. Diefenderfer DL, Osyczka AM, Reilly GC, Lebov PS (2005) BMP responsive-ness in human mesenchymal stem cells. Connect Tissue Res 46: 305–311.
17. Diefenderfer DL, Osyczka AM, Garino JP, Lebov PS (2003) Regulation of BMP-induced transcription in cultured human bone marrow stromal cells. J Bone Joint Surg Am 85: 19–28.
18. Puleo DA (1997) Dependence of mesenchymal stem cells responses on duration of exposure to bone morphogenetic protein-2 in vitro. J Cell Physiol 173: 93–101.
19. Hanada K, Dennis JE, Caplan AI (1997) Stimulatory effects of basic fibroblast growth factor and bone morphogenetic protein-2 on osseous differentiation of rat bone marrow-derived mesenchymal stem cells. J Bone Miner Res 12: 1606–1613.
20.forgren NR, Henriksen Z, Sorensen OH, Civitelli R (2004) Dexamethasone, BMP-2, and 1, 25-dihydroxyvitamin D enhance a more differentiated osteoblast phenotype: validation of an in vitro model for human bone marrow-derived primary osteoblasts. Steroids 69: 219–226.
21. Kyllonen L, Haimi S, Sakkinen J, Kuokkanen H, Mannenstrom B, et al. (2013) Exagonously added BMP-6, BMP-7 and VEGF may not enhance the osteogenic differentiation of human adipose stem cells. Growth Factors 31: 141–153.
22. Takagi K, Urini MR (1982) The role of bone marrow in bone morphogenetic protein-induced repair of femoral massive diaphyseal defects. Clin Orthop Relat Res 171: 224–231.
23. Waese EY, Kandel RA, Stanford WL (2008) Application of stem cells in bone repair. Skeletal Radiol 37: 601–608.
24. Stemper AF, Rackwitz L, Gilbert F, Noth U, Tuan RS (2012) Concise review: the clinical application of mesenchymal stem cells for musculoskeletal regeneration: current status and perspectives. Stem Cells Transl Med 1: 237–247.
25. Cui Q, Dighe AS, Irvine JN (2013) Combined angiogenic and osteogenic factor delivery for bone regenerative engineering. Curr Pharm Des 19: 3374–3383.
26. Peng H, Wright V, Usas A, Gearhart B, Shen HC, et al. (2002) Synergistic enhancement of bone formation and healing by stem cell-expressed VEGF and bone morphogenetic protein-4. J Clin Invest 110: 751–719.
27. Peng H, Usas A, Olszanski A, Ho AM, Gearhart B, et al. (2005) VEGF improves, whereas sFlt1 inhibits, BMP2-induced bone formation and bone healing through modulation of angiogenesis. J Bone Miner Res 20: 2017–2027.
28. Roldan JC, Detsch R, Schaefer S, Chang E, Kelantan M, et al. (2010) Bone formation and degradation of a highly porous biphasic calcium phosphate ceramic in presence of BMP-7, VEGF and mesenchymal stem cells in an ectopic mouse model. J Craniomaxillofac Surg 38: 423–430.
29. Li JZ, Li H, Sasaki T, Holman D, Beres B, et al. (2003) Osteogenic potential of five different recombinant human bone morphogenetic protein adenoviral vectors in the rat. Gene Ther 10: 1735–1743.
30. Kang Q, Sun MH, Cheng H, Peng Y, Montag AG, et al. (2004) Characterization of the distinct orthotopic bone-forming activity of 14 BMPs using recombinant adenovirus-mediated gene delivery. Gene Ther 11: 1312–1320.
31. Song K, Krause C, Shi S, Patterson M, Suto R, et al. (2010) Identification of a key residue mediating bone morphogenetic protein (BMP)-6 resistance to noggin inhibition allows for engineered BMPs with superior agonist activity. J Biol Chem 285: 12169–12180.
32. Cui F, Wang X, Liu X, Dighe AS, Balian G, et al. (2010) VEGF and BMP-6 enhance bone formation mediated by cloned mouse osteoprogenitor cells. Growth Factors 28: 306–317.
33. Wang X, Cui F, Madhu V, Dighe AS, Balian G, et al. (2011) Combined VEGF and LMP-1 delivery enhances osteoprogenitor cell differentiation and ectopic bone formation. Growth Factors 29: 36–48.
34. Seamon J, Wang X, Cui F, Keller T, Dighe AS, et al. (2013) Adenoviral Delivery of the VEGF and BMP-6 Genes to Rat Mesenchymal Stem Cells Potentiates Osteogenesis. Bone Marrow Res 2013: 737580.
35. Zhang Y, Madhu V, Dighe AS, Irvine JN Jr, Cui Q (2012) Osteogenic response of human adipose-derived stem cells to BMP-6, VEGF, and combined VEGF plus BMP-6 in vitro. Growth Factors 30: 333–343.
36. Diduch DR, Coe MR, Joyner C, Owen ME, Balian G (1993) Two cell lines from bone marrow that differ in terms of collagen synthesis, osteogenic characteristics, and matrix mineralization. J Bone Joint Surg Am 75: 92–105.
37. Dighe AS, Yang S, Madhu V, Balian G, Cui Q (2012) Interferon gamma and T cells inhibit osteogenesis induced by allogeneic mesenchymal stromal cells. J Orthop Res 31: 227–234.
38. Reed AA, Joyner CJ, Brownlow HC, Simpson AH (2002) Human atrophic fracture non-unions are not avascular. J Orthop Res 20: 593–599.
39. Sarahrudi K, Thomas A, Braunsteiner T, Wolf H, Vicsei V, et al. (2009) VEGF serum concentrations in patients with long bone fractures: a comparison between impaired and normal fracture healing. J Orthop Res 27: 1293–1297.
40. Mentink A, Hulsman M, Groen N, Licht R, Dechering KJ, et al. (2013) Predicting the therapeutic efficacy of MSC in bone tissue engineering using the molecular marker CADM1. Biomaterials 34: 4592–601.
41. Liu Y, Berendzen AD, Jia S, Lotinun S, Baron R, et al. (2012) Intracellular VEGF regulates the balance between osteoblast and adipocyte differentiation. J Clin Invest 122: 3101–3113.
42. Li G, Corsi-Payne K, Zheng B, Usas A, Peng H, et al. (2009) The dose of growth factors influences the synergistic effect of vascular endothelial growth factor on bone morphogenetic protein 4-induced ectopic bone formation. Tissue Eng Part A 15: 2123–2133.
43. Barbara NP, Wranza J, Letarte M (1999) Endoglin is an accessory protein that interacts with the signaling receptor complex of multiple members of the transforming growth factor-beta superfamily. J Biol Chem 274: 584–594.